Polaris News

28

Oct 16

ADI-PEG 20 Can Boost Anti-Tumor Immune Surveillance

SAN DIEGO, Oct. 24, 2016 /PRNewswire/ -- Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology and Immunotherapy conference in Boston. These findings suggest that...
Read More

6

Jun 16

FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors

CHICAGO, June 6, 2016 /PRNewswire/ -- Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in argininosuccinate synthetase (ASS1) deficient thoracic tumors. The results were generated during analysis of an ongoing phase 1 study that...
Read More

6

Jun 16

Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma

CHICAGO, June 6, 2016 /PRNewswire/ -- Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median...
Read More

3

Jun 16

ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

SAN DIEGO, June 3, 2016 /PRNewswire/ -- Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI-PEG 20 with gemcitabine and nab-Paclitaxel (ADIGemPac) in patients with advanced pancreatic cancer. The results will be presented at the American Society...
Read More

16

May 16

Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI-PEG 20

SAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI-PEG 20 which Polaris Group plans to commercialize upon...
Read More

5

May 16

Polaris Group’s ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma When Combined with Standard First-Line Chemotherapy Regimen

SAN DIEGO, May 5, 2016 – Polaris Group announced results from an ongoing phase 1 study that combines its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant pleural mesothelioma (MPM) demonstrating promising response rates. Dr. Peter Szlosarek from Barts Cancer...
Read More

15

Feb 16

Polaris Group Shares Listed on the Emerging Stock Board of the Taipei Exchange

Taipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx). Shares of Polaris Group are traded under stock code 6550. CTBC Bank is acting as transfer agent for shares of Polaris Group....
Read More

22

Jan 16

Polaris Group Completes Construction of Its GMP Manufacturing Facility in China

SAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China. The construction broke ground in November 2013 and covers 11.3 acres in Chengdu High-tech Park....
Read More